EU funding for CombiGene’s epilepsy project is directly relevant for Panion’s epilepsy project
Tuesday the 15.th of May, late afternoon, CombiGene’s CEO Jan Nilsson released the news that the EU framework programme for research and development, Horizon 2020, will invest 3.6 million euros in CombiGene’s ongoing development and commercialization of their gene therapy project focusing on difficult-to-treat epilepsy in humans. During 2017, CombiGene presented three successful preclinical studies in the development of a gene-therapeutic treatment of difficult-to-treat epilepsy in humans. In January 2018, CombiGene chose British CGT Catapult as a partner for development of a complete and finalized manufacturing method that will enable to proceed with commercial GMP manufacturing and subsequent clinical trials. The EU capital injection means that they can continue the product and business development exactly according to plan and without delay.
“In Panion, we are really enthusiastic about this good result for CombiGene and we congratulate them with a successful outcome and the prospect of moving forward fast” says Anja Holm, CEO of Panion. “The development of CombiGene’s epilepsy project has direct links to Panion’s epilepsy project, due to our license agreement for development of the gene therapy product for epileptic dogs and cats. It is therefore also very good news for us, and we expect an increased interest in the new emission of shares that starts just today.”
Anja E. H. Holm, CEO
+ 45-22 94 66 00
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.